Leukemia News

The FDA announced several regulatory actions the past few weeks.

The FDA placed a partial clinical hold on studies of magrolimab as treatment for acute myeloid leukemia, the agent’s manufacturer announced.

An investigational chimeric antigen receptor T-cell therapy induced responses among patients with indolent lymphomas, according to topline data released by the agent’s manufacturer.

Nirali N. Shah, MD, MHSc, was a self-proclaimed “big math nerd” growing up.

A pathfinder spaceflight investigation has flown to the International Space Station with a goal of expanding a population of hematopoietic stem cells that retain their multipotency.

The FDA placed a formal clinical hold on a phase 1 trial that has been paused since the death of a study participant more than 2 months ago.

Misdiagnoses of myelodysplastic syndrome appeared common among patients included in MDS Natural History Study, according to study results published in Blood Advances.

This year’s ASCO Annual Meeting included essential research updates across the field.

In this edition, FDA approves Vanflyta for newly diagnosed AML; liso-cel could have ‘best shot’ at remission for double refractory CLL; mortality factors among cancer survivors and more.

The University of Texas MD Anderson Cancer Center has retained its distinction as the No. 1 cancer hospital in the country.